- Home
- WRN vs PRQR Comparison
WRN vs PRQR Comparison
Compare WRN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- PRQR
- Stock Information
- Founded
- WRN 2006
- PRQR 2012
- Country
- WRN Canada
- PRQR Netherlands
- Employees
- WRN N/A
- PRQR N/A
- Industry
- WRN Metal Mining
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- PRQR Health Care
- Exchange
- WRN Nasdaq
- PRQR Nasdaq
- Market Cap
- WRN 248.0M
- PRQR 224.4M
- IPO Year
- WRN N/A
- PRQR 2014
- Fundamental
- Price
- WRN $1.99
- PRQR $2.45
- Analyst Decision
- WRN Strong Buy
- PRQR Strong Buy
- Analyst Count
- WRN 2
- PRQR 8
- Target Price
- WRN $4.13
- PRQR $8.88
- AVG Volume (30 Days)
- WRN 732.6K
- PRQR 404.0K
- Earning Date
- WRN 11-06-2025
- PRQR 11-06-2025
- Dividend Yield
- WRN N/A
- PRQR N/A
- EPS Growth
- WRN N/A
- PRQR N/A
- EPS
- WRN N/A
- PRQR N/A
- Revenue
- WRN N/A
- PRQR $20,129,184.00
- Revenue This Year
- WRN N/A
- PRQR N/A
- Revenue Next Year
- WRN N/A
- PRQR N/A
- P/E Ratio
- WRN N/A
- PRQR N/A
- Revenue Growth
- WRN N/A
- PRQR 8.65
- 52 Week Low
- WRN $0.90
- PRQR $1.07
- 52 Week High
- WRN $2.06
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- WRN 75.31
- PRQR 64.34
- Support Level
- WRN $1.87
- PRQR $2.08
- Resistance Level
- WRN $2.06
- PRQR $2.19
- Average True Range (ATR)
- WRN 0.10
- PRQR 0.13
- MACD
- WRN 0.01
- PRQR 0.02
- Stochastic Oscillator
- WRN 84.78
- PRQR 99.10
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.